Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges in the Development of Therapy for Dry Age-Related Macular Degeneration.

Advances in experimental medicine and biology - 1 Jan 2016

Wei Cynthia X, Sun Aixu, Yu Ying, Liu Qianyong, Tan Yue-Qing, Tachibana Isamu, Zeng Hong, Wei Ji-Ye

Abstract excerpt

Dry age-related macular degeneration (AMD), a multifactorial progressive degenerative disease of the retinal photoreceptors, pigmented epithelium and Bruch's membrane/choroid in central retina, causes visual impairment in millions of elderly people worldwide. The only available therapy for this disease is the over-the-counter (OTC) multi-vitamins plus macular xanthophyll (lutein/zeaxanthin) which attempts to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Drug Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genetic Therapy

Share to Geographic Atrophy

Share to Mice, Inbred C57BL

Share to Mutation

Share to Stem Cell Transplantation

Source

Identifiers

PMID: 26427400
DOI: 10.1007/978-3-319-17121-0_15

Genes

OTC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges in the Development of Therapy for Dry Age-Related Macular Degeneration.PMID 26427400Read ↗

Mechanistic Analysis of Luteolin in Mitigating Dry Age-Related Macular Degeneration through Network Pharmacology and Experimental ValidationSemantic proximity Read ↗

Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome MeasuresSemantic proximity Read ↗

The putative role of lutein and zeaxanthin as protective agents against age-related macular degeneration: promise of molecular genetics for guiding mechanistic and translational research in the fieldSemantic proximity Read ↗

Lutein and zeaxanthin: Production technology, bioavailability, mechanisms of action, visual function, and health claim statusSemantic proximity Read ↗

A Systematic Review; Efficacy Assessment of Novel Therapy in Treating Age-related Macular DegenerationSemantic proximity Read ↗

Beacon of Hope for Age-Related Retinopathy: Antioxidative Mechanisms and Pre-Clinical Trials of Quercetin TherapySemantic proximity Read ↗

Role of flavonoids in age-related macular degenerationSemantic proximity Read ↗

Human aging and disease: Lessons from age-related macular degenerationSemantic proximity Read ↗

The emerging roles of the macular pigment carotenoids throughout the lifespan and in prenatal supplementationSemantic proximity Read ↗

The mechanisms of natural products for eye disorders by targeting mitochondrial dysfunctionSemantic proximity Read ↗

Pilot evaluation of short-term changes in macular pigment and retinal sensitivity in different phenotypes of early age-related macular degeneration after carotenoid supplementation.Semantic proximity Read ↗

Targeting IDO1 Suppresses RPE Ferroptosis and NLRP3 Inflammasome Activation and Ameliorates NaIO₃-Induced dry age-related macular degenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.